Regeneron secures $2.3B potential partnership, gains EMA accelerated review for Otarmeni
REGN sits 34% above its 52-week low of $476.487.
Summary
Regeneron announced a new research partnership with Parabilis, securing $50 million upfront, $75 million in equity, and up to $2.2 billion in potential milestones for antibody-helicon conjugates. Concurrently, the EMA accepted Otarmeni for accelerated review, a significant step towards market approval. Additionally, its maftivimab showed lab activity against Bundibugyo ebolavirus and is under WHO evaluation. This suite of positive developments continues Regeneron's recent strong momentum, following multiple drug approvals and positive trial results. The EMA's accelerated review for Otarmeni is a key near-term catalyst, potentially bringing a new drug to market faster.
At the time of this announcement, REGN was trading at $637.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $67B. The 52-week trading range was $476.49 to $821.11. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.